Shigeo Takahashi

Shigeo Takahashi

Auto-generated profile, based on publicly available information

Shigeo Takahashi

Department of Radiation Oncology, Kagawa University Hospital, Kagawa, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
TKTomoki Kimura
Tomoki Kimura
HAHiroshi Aikata
Hiroshi Aikata
STShigeo Takahashi
Shigeo Takahashi
ITIppei Takahashi
Ippei Takahashi
INIkuno Nishibuchi
Ikuno Nishibuchi
YNYasushi Nagata
Yasushi Nagata

12 June 2017 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KOKeiichi Okano
Keiichi Okano
HSHironobu Suto
Hironobu Suto
MOMinoru Oshima
Minoru Oshima
EMEri Maeda
Eri Maeda
NYNaoki Yamamoto
Naoki Yamamoto
YSYasuyuki Suzuki
Yasuyuki Suzuki

7 November 2012 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
TKTomoki Kimura
Tomoki Kimura
STShigeo Takahashi
Shigeo Takahashi
MKMasahiro Kenjo
Masahiro Kenjo
INIkuno Nishibuchi
Ikuno Nishibuchi
ITIppei Takahashi
Ippei Takahashi
YNYasushi Nagata
Yasushi Nagata

14 January 2018 in Hepatology Research
Verified
Journal Article
Open access
PDF file
KKKatsumaro Kubo
Katsumaro Kubo
TKTomoki Kimura
Tomoki Kimura
HAHiroshi Aikata
Hiroshi Aikata
STShigeo Takahashi
Shigeo Takahashi
YTYuki Takeuchi
Yuki Takeuchi
YNYasushi Nagata
Yasushi Nagata
Aim: To evaluate the long‐term outcome of stereotactic body radiotherapy in patients with small hepatocellular carcinoma who were ineligible for resection or ablation therapies.Methods: A total of 65 patients with 74 hepatocellular carcinomas (median tumor size 16 mm) were enrolled in the present study. They were treated with the prescribed dose of 48 Gy in four fractions at the isocenter. We extended the observation period and analyzed long‐term outcomes, including overall survival, progression‐free survival, local control, and various prognostic factors, in these patients.Results: The median follow‐up period was 41 months for all patients and 62 months for surviving patients. The 3‐ and 5‐year overall survival rates were 56.3% (95% confidence interval, 44.1–68.5%) and 41.4% (95% confidence interval, 28.7–54.1%), respectively. The 3‐ and 5‐year progression‐free survival rates were 25.4% (95% confidence interval, 14.0–36.8%) and 10.6% (95% confidence interval, 1.5–19.8%), respectively. The 3‐ and 5‐year local control rates were both 100% (95% confidence interval 100%). Liver toxicities exceeding grade 3 were observed in 15 patients (23.1%). The proportion of patients who had grade ≥3 toxicities did not increase. Adverse effects (grade ≤2) presented as significant prognostic factors of overall survival, while TNM stage (T1N0M0) was a significant prognostic factor of progression‐free survival after multivariate analysis.Conclusions: Stereotactic body radiotherapy was effective for patients with small hepatocellular carcinomas who were ineligible for resection or ablation therapies. The incidence of grade ≥3 adverse effects did not increase, even after longer follow‐up times.

11 June 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
TKTomoki Kimura
Tomoki Kimura
STShigeo Takahashi
Shigeo Takahashi
ITIppei Takahashi
Ippei Takahashi
INIkuno Nishibuchi
Ikuno Nishibuchi
YDYoshiko Doi
Yoshiko Doi
YNYasushi Nagata
Yasushi Nagata
This study aimed to evaluate the dynamic computed tomographic (CT) appearance of focal radiation injury to cirrhotic liver tissue around the tumor following stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma (HCC). Seventy-seven patients with 92 HCCs were observed for >6 months. Sixty-four and 13 patients belonged to Child–Pugh class A and B, respectively. The median SBRT dose was 48 Gy/4fr. Dynamic CT scans were performed in non–enhanced, arterial, portal, and venous phases. The median follow-up period was 18 months. Dynamic CT appearances were classified into 3 types: type 1, hyperdensity in all enhanced phases; type 2, hypodensity in arterial and portal phases; type 3, isodensity in all enhanced phases. Half of the type 2 or 3 appearances significantly changed to type 1, particularly in patients belonging to Child–Pugh class A. After 3–6 months, Child–Pugh class B was a significant factor in type 3 patients. Thus, dynamic CT appearances were classified into 3 patterns and significantly changed over time into the enhancement group (type 1) in most patients belonging to Child–Pugh class A. Child–Pugh class B was a significant factor in the non–enhancement group (type 3).

18 January 2015 in Journal of Radiation Research
Verified
Journal Article
Open access
PDF file
TKTomoki Kimura
Tomoki Kimura
YDYoshiko Doi
Yoshiko Doi
TNTakeo Nakashima
Takeo Nakashima
NINobuki Imano
Nobuki Imano
TKTsuyoshi Katsuta
Tsuyoshi Katsuta
YNYasushi Nagata
Yasushi Nagata
The purpose of this study was to evaluate the efficacy and safety of volumetric modulated arc therapy (VMAT) after extrapleural pneumonectomy (EPP) in patients with malignant pleural mesothelioma (MPM). A total of 15 patients who received VMAT after EPP were enrolled. All patients were males, and the median age was 67 years (Stage IB in two, II in six, and III in seven patients). The clinical target volume (CTV) included the entire preoperative ipsilateral hemithorax and involved nodal stations. The CTV was generally expanded by 10–15 mm beyond the planning target volume (PTV). The dose prescription was designed to cover 95% of the PTV with 54 Gy in 30 fractions. The median follow-up period was 11 months. Treatment-related toxicities were evaluated by Common Terminology Criteria for Adverse Events (CTCAE) ver. 4. One-year local control, disease-free survival, and overall survival rates were 55.7% [95% confidence interval (CI): 25.6–85.8%], 29.3% (95% CI: 5.3–53.3%), and 43.1% (95% CI: 17.1–69.0%), respectively. According to the histological analysis, the one-year LC rate was significantly worse in patients with non-epithelial type (biphasic and sarcomatoid types) than in patients with epithelial type [epithelial type: 83.3% (95% CI, 53.5–100%), non-epithelial type: 0% (95% CI, 0%), P = 0.0011]. Grade 3 pneumonitis after VMAT was observed in three patients (20.0%); however, no patients died of pulmonary toxicity. VMAT appears to be relatively safe for patients with MPM after EPP because of the low pulmonary dose.